KR20240014328A - Weissella cibaria having effects of preventing or improving oral disease and the use thereof - Google Patents

Abstract

The present invention relates to Weissella sibaria strains that have the effect of preventing or improving oral diseases and their uses. The Weissella sybaria strain of the present invention has excellent antibacterial activity against oral pathogenic bacteria and an excellent ability to suppress the expression of etiological factors of oral pathogenic bacteria, showing an excellent preventive or improvement effect on oral diseases such as dental caries, periodontal disease, and bad breath removal.

Description

Weissella cibaria strains with oral disease prevention or improvement effects and their uses {WEISSELLA CIBARIA HAVING EFFECTS OF PREVENTING OR IMPROVING ORAL DISEASE AND THE USE THEREOF}

The present invention relates to Weissella sibaria strains that have the effect of preventing or improving oral diseases and their uses.

The human oral cavity can be maintained in a healthy state by a well-balanced population of more than 700 types of normal microflora. However, when the balance of normal microflora is disrupted, such as an increase in harmful microorganisms and a decrease in beneficial microorganisms, oral diseases such as periodontal disease and dental caries occur. Streptococcus mutans ( S. mutans ), known as the causative agent of cavities, is a Gram-positive, facultative anaerobic bacterium that causes dental caries. In particular, the biofilm produced by S. mutans has strong resistance to antibiotics and immune cell attacks, making eradication difficult. Porphyromonas gingivalis (P.gingivalis ) is a Gram-negative, anaerobic bacterium that causes gum inflammation and, as a result of inflammation, induces destruction of alveolar bone, causing tooth loss. P. gingivalis produces gingipain, a powerful proteolytic enzyme that dissolves bones and gums, and has the characteristic of infiltrating immune cells. Fusobacterium nucleatum ( F. nucleatum ) is a Gram-negative, anaerobic bacterium that produces plaque using adhesion molecules (FadA adhesin) and helps the attachment of other bacteria, contributing to the development of stomatitis, tooth decay, gingivitis, and periodontitis. In addition, it has been found to be closely related to endocarditis, liver abscess, urinary infection, and colon cancer as a result of systemic circulation.

Traditional methods of treating oral diseases include scaling, which physically removes tartar, and disinfection using antibiotics, but alternative treatments are required due to problems with antibiotic resistance. Recently, the use of probiotics, beneficial bacteria, has been emerging as an alternative therapy. It has been reported that the use of probiotics can play a role in restoring the balance of oral microorganisms that have lost the balance of normal microflora, and some probiotics have excellent antibacterial properties against oral pathogenic bacteria and anti-inflammatory properties that alleviate the inflammatory response induced by bacteria. It has been reported that it is effective.

Inspired by this, the present inventors completed the present invention by confirming the main functionality against oral pathogenic bacteria by Weissella cibaria SPM402 (hereinafter referred to as WC402), a probiotic isolated from kimchi, a traditional fermented food.

To solve the above problems

One embodiment of the present invention is

Weissella cibaria SPM 402 strain with the accession number KCCM 13206P is provided.

To solve the above problems

Another embodiment of the present invention is

The above strains; its shredded material; its culture; Fermented products thereof; and extracts of the strains, lysates, cultures, or fermentations; Provided is a composition for preventing or improving periodontal disease comprising one or more of the following.

One embodiment of the present invention to achieve the above object is

It is a Weissella cibaria SPM 402 strain with the accession number KCCM 13206P.

Hereinafter, the present invention will be described in detail.

In one aspect of the present invention, a strain is provided that reduces the production of IL-1β and IL-8.

One aspect of the present invention provides a Weissella cibaria strain that has antibacterial activity against oral harmful microorganisms.

In one aspect of the present invention, the strain provides a strain that has a periodontal disease prevention, improvement or treatment effect.

In one aspect of the present invention, the strain is selected from the group consisting of periodontal disease-causing microorganisms, Streptococcus mutans , Porphyromonas gingivalis , and Fusobacterium nucleatum . Strains with antibacterial activity against one or more of the selected substances are provided.

In one aspect of the present invention, the strain provides a strain that has an effect in preventing, improving, or treating dental caries.

In one aspect of the present invention, the strain is selected from the group consisting of dental caries-causing microorganisms Streptococcus mutans , Porphyromonas gingivalis , and Fusobacterium nucleatum . Provides strains that have antibacterial activity against one or more of the selected substances.

In one aspect of the present invention, the strain provides a strain that has a bad breath removal or prevention effect.

In one aspect of the present invention, the bad breath-causing microorganism is any selected from the group consisting of Streptococcus mutans , Porphyromonas gingivalis , and Fusobacterium nucleatum . Provides one or more strains with antibacterial activity.

In one aspect of the present invention, the strain is Weissella cibaria SPM 402.

In one aspect of the present invention, the strain provides a strain whose accession number is KCCM 13206P.

Another aspect of the present invention is a strain according to any one of the above aspects of the present invention; its shredded material; its culture; Fermented products thereof; and extracts of the strains, lysates, cultures or fermentations; Provided is a microbial preparation comprising one or more of the following.

Another aspect of the present invention is a strain according to any one of the above aspects of the present invention; its shredded material; its culture; Fermented products thereof; and extracts of the strains, lysates, cultures or fermentations; It provides a method of preventing, improving or treating periodontal disease to a subject in need of prevention, improvement or treatment of periodontal disease, including the step of using one or more of the following.

Another aspect of the present invention is a strain according to any one of the above aspects of the present invention; its shredded material; its culture; Fermented products thereof; and extracts of the strains, lysates, cultures or fermentations; A method for preventing, improving, or treating dental caries is provided to a subject in need of preventing, improving, or treating dental caries, including the step of using one or more of the following.

Another aspect of the present invention is a strain according to any one of the above aspects of the present invention; its shredded material; its culture; Fermented products thereof; and extracts of the strains, lysates, cultures or fermentations; A method for preventing, improving, or eliminating bad breath is provided to a subject in need of preventing, improving, or eliminating bad breath, including using one or more of the following.

Another aspect of the present invention is a strain according to any one of the above aspects of the present invention; its shredded material; its culture; Fermented products thereof; and extracts of the strains, lysates, cultures or fermentations; Provides a composition for preventing, improving or treating periodontal disease comprising one or more of the following.

In one embodiment, the composition provides a composition for preventing, improving or treating periodontal disease, which is a health functional food composition.

In one embodiment, the composition may be a pharmaceutical composition, health functional food, or pharmaceutical composition.

Another aspect of the present invention is a strain according to any one of the above aspects of the present invention; its shredded material; its culture; Fermented products thereof; and extracts of the strains, lysates, cultures or fermentations; Provided is a composition for preventing, improving or treating dental caries comprising one or more of the following.

In one embodiment, the composition provides a composition for preventing, improving, or treating dental caries, further comprising zinc.

In one embodiment, the composition provides a composition for preventing, improving, or treating dental caries, which is a health functional food composition.

In one embodiment, the composition may be a pharmaceutical composition, health functional food, or pharmaceutical composition.

Another aspect of the present invention is a strain according to any one of the above aspects of the present invention; its shredded material; its culture; Fermented products thereof; and extracts of the strains, lysates, cultures or fermentations; Provided is a composition for removing, improving or preventing bad breath comprising one or more of the following.

In one embodiment, the composition provides a composition for removing, improving or preventing bad breath, which is a health functional food composition.

In one embodiment, the composition may be a pharmaceutical composition, health functional food, or pharmaceutical composition.

According to one exemplary embodiment, the composition may be a pharmaceutical composition.

The term "prevention" of the present invention refers to any action that suppresses or delays the onset of a disease by administering the pharmaceutical composition according to the present invention, and the term "treatment" refers to any action that prevents or delays the onset of a disease by administering the pharmaceutical composition according to the present invention. It refers to any action that improves or changes the symptoms of a suspected or diseased entity.

The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent, and the carrier may include a non-naturally occurring carrier.

More specifically, carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate. , calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, polycaprolactone, polylactic solution. Examples include poly lactic acid, poly-L-lactic acid, and mineral oil.

The pharmaceutical composition can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injectable solutions according to conventional methods. , the form of the carrier may include various amorphous carriers, microspheres, nanofibers, etc.

When formulated, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations include the extract and its fractions with at least one 19-9 excipient, such as starch, calcium carbonate ( It can be prepared by mixing calcium carbonate, sucrose or lactose, gelatin, etc. Additionally, in addition to simple excipients, lubricants such as magnesium styrate and talc may also be used.

Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. there is.

Preparations for parenteral administration may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, etc. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate.

In addition, the term "improvement" in the present invention means any action that reduces at least the degree of symptoms, for example, parameters related to the condition being treated by administering the pharmaceutical composition according to the present invention.

The term "health functional food" in the present invention refers to food manufactured and processed using raw materials or ingredients with functionality useful to the human body in accordance with Act No. 6727 on Health Functional Food, and "functionality" refers to the structure of the human body. It means controlling nutrients for functions or obtaining useful effects for health purposes such as physiological effects. Meanwhile, health food refers to food that has a more active health maintenance or promotion effect compared to general food, and health supplement refers to food for health supplement purposes. In some cases, the terms health functional food, health food, and health supplement food are used. can be used interchangeably.

According to one exemplary embodiment, the composition may be a food composition. The food composition may be in a liquid or solid form, for example, various foods, beverages, gums, teas, vitamin complexes, health supplements, etc., and may be used in the form of powders, granules, tablets, capsules, or beverages. You can. In addition to the active ingredients, the food composition of each formulation can be appropriately selected and mixed by a person skilled in the art according to the formulation or purpose of use, without difficulty, and a synergistic effect can occur when applied simultaneously with other raw materials. There are no particular restrictions on the liquid ingredients that can be contained in addition to the active ingredients disclosed in this specification, and, like regular beverages, various flavoring agents or natural carbohydrates can be included as additional ingredients. Examples of the natural carbohydrates include monosaccharides, disaccharides such as glucose and fructose, polysaccharides such as maltose and sucrose, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. etc. As the above flavoring agents, natural flavoring agents (thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.) can be advantageously used. The ratio of the natural carbohydrate may be generally about 1 to 20 g, and in one aspect about 5 to 12 g, per 100 ml of the composition disclosed herein. In one aspect, the food composition may contain various nutrients, vitamins, minerals ( electrolytes), flavoring agents such as synthetic and natural flavors, colorants and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, It may contain preservatives, glycerin, alcohol, carbonating agents used in carbonated drinks, etc.

In one embodiment, the composition may be provided in the form of toothpaste or mouthwash.

In one embodiment, the composition can be used on humans.

In one embodiment, the composition can be used to remove bad breath in animals other than humans, preferably companion animals, and more preferably dogs and cats.

The Weissella sybaria strain of the present invention has excellent antibacterial activity against oral pathogenic bacteria and an excellent ability to suppress the expression of etiological factors of oral pathogenic bacteria, showing an excellent preventive or improvement effect on oral diseases such as dental caries, periodontal disease, and bad breath removal.

Meanwhile, the effects that can be obtained from the present invention are not limited to the effects mentioned above, and other effects not mentioned will be clearly understood by those skilled in the art from the description below. You will be able to.

Figure 1 shows the results of macrogen identification of WC402.
Figure 2 shows the inhibitory effect of WC402 on P. gingivalis Kgp activity.
Figure 3 shows the inhibitory effect of WC402 on P. gingivalis Rgp activity.
Figure 4 shows the biofilm formation inhibition ability of WC402.
Figure 5 shows the ability of WC402 to suppress expression of the fadA gene, a etiological factor of F. nucleatum .
Figure 6 shows the relative quantification of pro-inflammatory cytokine gene expression in the YD-38 human oral epithelial cell line infected with F. nucleatum and treated with WC402.
Figure 7 shows the effect of WC 402 on IL-8 production in YD-38 human oral epithelial cell line infected with F. nucleatum .

Hereinafter, embodiments of the present invention will be described in more detail. Embodiments of the present invention can be modified in various forms, and the scope of the present invention should not be construed as being limited to the following embodiments. This example is provided to more completely explain the present invention to those skilled in the art.

Example 1. Strain and culture conditions

The lactic acid bacteria used in this experiment were isolated using commercially available kimchi as a sample. 10 g of kimchi was homogenized in 100 ml of PBS solution, serially diluted 10 times with PBS, and 0.1 ml of each dilution step was spread on MRS solid medium. After culturing at 37°C for 24 hours, milky colonies were selected and subcultured. . The strain derived from this, Weissella cibaria SPM402 (WC402), was identified through 16S rRNA sequencing at Macrogen (Seoul), and the results are shown in Figure 1. The selected Weissella cibaria SPM402 (WC402) strain was deposited at the Korea Microbial Conservation Center and received deposit number KCCM 13206P on June 14, 2022.

Oral pathogenic bacteria used in this experiment Porphyromonas gingivalis (P. gingivalis) KCTC 5352, Fusobacterium nucleatum (F. nucleatum spp. Nucleatum) KCTC 2640, Streptococcus mutans ( Streptococcus mutans , S. mutans) KCTC 3065, Lactobacillus casei ( L.casei ) KCTC 2180, Prevotella intermedia ( P.intermedia ) KCTC 15693 from the Biological Resources Center (KCTC, Jeongeup, Jeollabuk-do) We used strains that had been purchased and stored in our laboratory.

WC402, a lactic acid bacterium, was cultured anaerobically at 37°C on MRS medium, P. gingivalis was cultured anaerobically on Brain Heart Infusion (BHI, Bacto ^TM ) medium containing 5% horse blood, and F. nucleatum was cultured anaerobically on medium. Anaerobic culture was performed at 37°C in Reinforced Clostridial medium (Difco), and cultured in S. mutans BHI medium at 37°C using the candle jar method.

Example 2. Cell lines and culture methods

YD-38 cell line (KCLB, KOREA), a human periodontal epithelial cell, was purchased from the Korea Cell Line Bank and grown in RPMI1640 medium with L-glutamine (300 mg/ml), 25mM HEPES, 25mM _NaHCO3, 10% FBS, and penicillin/streptomycin. was cultured in an environment of 37°C and 5% CO2 using medium supplemented with , and subcultured at 2-day intervals.

Experimental Example 1 . In vitro Antibacterial activity measurement

The antibacterial activity of WC402 in culture media of oral pathogenic bacteria was tested using the microdilution method. WC402 culture medium was serially diluted 2-fold to the highest concentration of 50%, and P. gingivalis KCTC 5352, F. nucleatum spp. was added at a concentration of 1x10 ⁶ CFU/ml. After culturing nucleatum KCTC 2640, S. mutans KCTC 3065, L.casei KCTC2180, and P.intermedia KCTC15693 at 37°C for 48 hours, the growth of the bacteria was confirmed and the concentration of the WC402 supernatant where growth was inhibited was determined at Minimum Inhibitory Concentration. MIC), and after confirming the MIC, inoculate 10 ㎕ of each culture medium without WC402 culture supernatant. After culturing at 37°C for 48 hours, the lowest concentration at which bacterial growth cannot be confirmed is the minimum sterilizing concentration. (Minimum Bactericidal Concentration, MBC) was determined. For quality control, the antibacterial activity was measured using ampicillin for S. mutans and P. gingivalis , and moxifloxacin for F. nucleatum, and the results are shown in Table 1 below.

[Table 1]

WC402 culture supernatant showed an antibacterial effect against major oral pathogenic bacteria, and in particular, it was confirmed that the growth of the strain was inhibited against P. gingivalis at a concentration of 5% of the culture supernatant, showing that it had an excellent antibacterial effect (Table 1)

Experimental Example 2. Ability to inhibit gingipain enzyme activity

Enzyme solution preparation

The ability of WC402 culture supernatant to inhibit P. gingivalis -derived gingipain enzyme was measured using fluorescent peptide as a substrate. After culturing P. gingivalis using the method described above, the cells were centrifuged to obtain extracellularly secreted enzyme (cell free gingipain, CFG), and the supernatant was filtered through 0.2 ㎛ filter paper. The enzyme solution (cell associated gingipain, CAG) attached to the non-secreted cell membrane was used by suspending the bacterial cells harvested by centrifuging the bacterial culture in phosphate buffer solution to an absorbance of 4.0 at 600 nm. To inhibit serine protease enzyme activity, 0.2 mM phenylmethanesulfonyl fluoride (PMSF, Sigma Co. St. Louis, USA) was added to the enzyme solution, then divided into portions and stored at -70°C.

Enzyme activity measurement

Each enzyme stock solution containing 1mM cysteine was diluted 10 times, and 20 ml was pre-incubated at 37°C for 10 minutes. Freeze-dried culture supernatant of WC402 was added at various concentrations, and the fluorescent substrate BOC-VLK-AMC (Peptide Institute. Inc., Japan) or BOC-VPR-AMC (Bachem Americas Inc., Canada) was added at a concentration of 0.2 mM. After reaction at 37°C for 15 minutes, 50 μl of 1.5 mM TLCK (Tosyllysine Chloromethyl Ketone) was added to terminate the reaction. The fluorescence of the substrate degradation products degraded by gingipain was measured (excitation at 360 nm, emission at 465 nm) using a fluorescence plate reader (Tecan ^TM ). Leupeptin (10 μM) was used as a positive control enzyme inhibitor, and the results of measuring enzyme activity are shown in Figures 2 and 3.

Gingivalis is a representative proteolytic enzyme produced by P. gingivalis . This enzyme plays a role in supplying nutrients to bacteria, but in humans, it is a major etiological factor that worsens disease conditions such as gum decay. This enzyme is divided into arginin specific gingipain (Rgp) and lysine specific gingipain (Kgp), and the inhibitory ability for both enzymes was confirmed. Leupeptin, a positive control substance, inhibited Kgp activity by about 78% and Rgp activity by about 90% at 10 uM, and the freeze-dried product of WC402 culture supernatant inhibited both Kgp and Rgp by about 78-80% at a concentration of 5 mg/mL, making it an effective gingipain. It was confirmed that it had an inhibitory effect.

Experimental Example 3. WC 402 S. mutans Biofilm formation inhibition ability of KCTC 3065

Biofilm formation was performed by modifying the method using crystal violet. After culturing S. mutans KCTC 3065 in BHI liquid medium for 24 hours at 37°C with 5% CO ₂ , the absorbance of S. mutans was measured to adjust the number of bacteria, and 10 ㎕ (3Х107 cells) of lyophilized culture solution was used at various concentrations. It was inoculated into 190 ㎕ of BHI medium containing 5% CO ₂ and cultured at 37°C for 24 h. After removing the supernatant, 200 mL of 10% formaldehyde (Sigma Co. St. Louis, USA) was added to each well and removed after 30 minutes. After washing three times with distilled water, 200 ㎕ of 0.5% crystal violet (Sigma Co. St. Louis, USA) was added to each well, and the biofilm was stained for 30 minutes. After washing three times with distilled water, each well was treated with 200 ㎕ of isopropyl alcohol and reacted for 1 hour to elute crystal violet. The absorbance of the eluted crystal violet was measured at 490 nm. At this time, the absorbance value of the biofilm of the untreated well was used as a control group and the well treated only with S. mutans was converted to 100% for comparative calculation, and the results are shown in Figure 4. WC402 freeze-dried culture medium inhibited biofilm formation by 54% at 1.25 mg/mL and 97% at 5 mg/mL, confirming its effective biofilm inhibition function.

Experimental Example 4. By WC 402 F. nucleatum etiological factor of fad Inhibition of A gene expression

After culturing F. nucleatum by the method of the above example, 10 ⁹ cfu of F. nucleatum was suspended in 3 ml Clostridia medium, freeze-dried WC402 culture was added at a concentration of 0.5 and 1 mg/mL, respectively, and incubated at 37°C for 6 hours. Cultured. Afterwards, the cells were harvested by centrifugation, and RNA was isolated using GeneAll Hybrid-R ^TM reagent (GeneAll, Seoul, KOREA). 200 ng of the isolated RNA was converted into c-DNA using AccuPower CycleScript RT premix (dN12) (Bioneer, Korea), and then qRT-PCR was performed to compare fad A gene expression. The result analysis was ddCt analysis, which performs relative quantitative analysis of fad A gene expression based on F. nucleatum 16S rRNA gene expression, and cases where the difference was 1.5 times or more were judged to be significant differences. As a result of the experiment, when only F. nucleatum was cultured, when fad A expression was set to 1, gene expression was approximately 0.67-fold when treated with 0.5 mg/mL WC402, and gene expression was approximately 0.49-fold when treated with 1 mg/mL WC402. This has decreased. (Figure 5)

Experimental Example 5. Effect of WC 402 culture medium on IL-8 and IL-1 β mRNA expression of periodontal epithelial cells

YD-38 cells were distributed in a 6-well plate at 5Х10 ⁵ cells/well and cultured for 24 hours. Then, the freeze-dried culture medium of WC402 was treated at a concentration of 0.5 mg/mL and 1 mg/mL, and after 30 minutes, F. nucleatum subsp. nucleatum (FN) induced an inflammatory response by treating 100 times more bacteria than the number of YD-38 cells. After 6 hours of incubation, RNA was isolated using the Hybrid-R ^TM (GeneAll, Seoul, Korea) kit using the triazole method. Using 0.1 mg of isolated RNA as a template, cDNA was synthesized using AccuPower CycleScript RT premix (dT20) (Bioneer, Daejeon, Korea), followed by quantitative real-time PCR targeting IL-1ß and IL-8. (qRT-PCR) was performed. The results were analyzed using ddCt analysis, which performs relative quantitative analysis of IL-1ß and IL-8 based on ß-actin, and a difference of more than 1.5-fold was judged to be significant expression inhibition.

The method for measuring IL-8 concentration using ELISA is as follows. To confirm that the production of pro-inflammatory cytokines in YD-38 cells treated with F. nucleatum was inhibited by WC402 culture medium, the human IL-1β ELISA kit and human IL-8 ELISA kit (Abcam, Cambridge, UK) were used as follows. They were analyzed together. YD-38 cell 5Х10 ⁵ cells were distributed per well in a 6-well plate and cultured for 24 hours. Then, WC 402 freeze-dried culture medium was treated at a concentration of 0.5 mg/mL and 1 mg/mL, and after 30 minutes, F. nuceatum was added at a ratio of 1:100. Treated and cultured for 24 hours. Using the culture supernatant as a sample, IL-8 was quantified according to the method provided by the manufacturer, and the concentration of IL-8 was calculated by substituting the absorbance value of each sample into a calibration curve prepared using standard IL-8.

As a result, the amount of IL-8 mRNA, the expression of which was induced 14 times by F. nucleatum, was suppressed by about 8.75 times when treated with 0.5 mg/mL of WC402, and by about 9.8 times when treated with 1 mg/mL of WC402. . Also, under the same conditions, the expression of IL-1β increased about 4.52-fold, but when treated with 0.5 mg/mL WC402, the expression was suppressed by about 1.86-fold and when treated with 1 mg/mL WC402, the expression was suppressed by about 2.7-fold. (Figure 6) As a result of comparing the amount of IL-8 produced after infection with F. nucleatum , IL-8 was 3850 ± 187.5 pg/mL when infected with only bacteria, and 2650 ± 112.5 pg/mL when treated with WC402 0.5 mg/mL, 1 mg/mL. When treated with mL, IL-8 production was significantly reduced to 1624 ± 76.3 pg/mL. (Figure 7)

The above detailed description is illustrative of the present invention. Additionally, the foregoing is intended to illustrate preferred embodiments of the present invention, and the present invention can be used in various other combinations, modifications, and environments. That is, changes or modifications can be made within the scope of the inventive concept disclosed in this specification, a scope equivalent to the written disclosure, and/or within the scope of technology or knowledge in the art. The written examples illustrate the best state for implementing the technical idea of the present invention, and various changes required for specific application fields and uses of the present invention are also possible. Accordingly, the detailed description of the invention above is not intended to limit the invention to the disclosed embodiments. Additionally, the appended claims should be construed to include other embodiments as well.

Korea Center for Microbial Conservation (KCCM) KCCM13206P 20220614

Claims (12)

Weissella cibaria SPM 402 strain with accession number KCCM 13206P, which has the effect of preventing or improving oral diseases. According to claim 1,
Having antibacterial activity against oral harmful microorganisms, including any one or more selected from the group consisting of Streptococcus mutans , Porphyromonas gingivalis , and Fusobacterium nucleatum Phosphorus, strain. According to claim 1,
The strain is a strain that has a periodontal disease prevention, improvement or treatment effect. According to claim 1,
A strain with anti-inflammatory effects that reduces the production of IL-1β and IL-8. According to claim 1,
The strain is a strain that has the effect of preventing, improving, or treating dental caries. According to claim 1,
The strain is a strain that has a bad breath removal, improvement or prevention effect. The strain according to any one of claims 1 to 6; its shredded material; its culture; Fermented products thereof; and extracts of the strains, lysates, cultures, or fermentations; A composition for preventing or improving periodontal disease comprising one or more of the following. According to claim 7,
The composition is a health functional food, a composition for preventing or improving periodontal disease. The strain according to any one of claims 1 to 6; its shredded material; its culture; Fermented products thereof; and extracts of the strains, lysates, cultures, or fermentations; A composition for preventing or improving dental caries comprising one or more of the following: According to clause 9,
The composition is a health functional food, a composition for preventing or improving dental caries. The strain according to any one of claims 1 to 6; its shredded material; its culture; Fermented products thereof; and extracts of the strains, lysates, cultures, or fermentations; A composition for removing or preventing bad breath comprising one or more of the following. According to claim 11,
The composition is a health functional food composition for removing, improving or preventing bad breath.